Company intelligence / Profile preview

Bioenamel

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

BioEnamel is a biotechnology company focused on developing biomimetic solutions for dental health, specifically targeting the regeneration of tooth enamel. The company's core technology utilizes amelogenin-derived peptides to facilitate the growth of hydroxyapatite crystals, mimicking the natural process of enamel formation. This approach aims to provide a permanent solution for tooth sensitivity and enamel erosion, moving beyond traditional fluoride treatments. BioEnamel's research originated from the University of Southern California (USC) and represents a significant advancement in restorative dentistry.

Therapeutic areas: OtherInfectious Diseases
Modalities: PeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Bioenamel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioenamel.

Explore the full profile